Robertson Courtney L, Saraswati Manda
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 1800 Orleans Street, Bloomberg Children's Center Room 6321, Baltimore, MD, 21287, USA,
J Bioenerg Biomembr. 2015 Apr;47(1-2):43-51. doi: 10.1007/s10863-014-9585-5. Epub 2014 Oct 28.
Progesterone has been studied extensively in preclinical models of adult traumatic brain injury (TBI), and has advanced to clinical trials in adults with TBI. However, there are very few preclinical studies in pediatric TBI models investigating progesterone for neuroprotection. Immature male and female rats (postnatal day, PND 17-21) underwent controlled cortical impact (CCI) to the left parietal cortex. Rats received either progesterone (10 mg/kg) at 1 h (i.p.) and 6 h (s.c.) after TBI or vehicle (22.5 % cyclohexdrin), and were compared to naïve, age-matched littermates. At 24 h after CCI, brain mitochondria were isolated from the ipsilateral hemisphere. Active (State 3) and resting (State 4) mitochondrial respiration were measured, and mitochondrial respiratory control ratio (RCR, State 3/State 4) was determined. Total mitochonidral glutathione content was measured. A separate group of rats were studied for histology, and received progesterone or vehicle every 24 h (s.c.) for 7 days. In male rats, TBI reduced mitochondrial RCR, and progesterone preserved mitochondrial RCR. This improvement of RCR was predominantly through significant decreases in State 4 respiratory rates. In female rats, post-injury treatment with progesterone did not significantly improve mitochondrial RCR. Normal (uninjured) male rats had lower mitochondrial glutathione content than normal female rats. After TBI, progesterone prevented loss of mitochondrial glutathione in male rats only. Tissue loss was reduced in progesterone treated female rats at 7d after CCI. Future studies will be directed at correlation with neurologic outcome testing. These preclinical studies could provide information for planning future clinical trials of progesterone treatment in children with TBI.
黄体酮已在成人创伤性脑损伤(TBI)的临床前模型中得到广泛研究,并已进入成人TBI的临床试验阶段。然而,在儿科TBI模型中,针对黄体酮神经保护作用的临床前研究却非常少。未成熟的雄性和雌性大鼠(出生后第17 - 21天)接受左侧顶叶皮质的控制性皮质撞击(CCI)。大鼠在TBI后1小时(腹腔注射)和6小时(皮下注射)接受黄体酮(10毫克/千克)或赋形剂(22.5%环己二醇),并与未受伤、年龄匹配的同窝幼崽进行比较。CCI后24小时,从同侧半球分离脑线粒体。测量活性(状态3)和静息(状态4)线粒体呼吸,并确定线粒体呼吸控制率(RCR,状态3/状态4)。测量线粒体总谷胱甘肽含量。另一组大鼠用于组织学研究,每24小时(皮下注射)接受黄体酮或赋形剂,持续7天。在雄性大鼠中,TBI降低了线粒体RCR,而黄体酮保留了线粒体RCR。RCR的这种改善主要是通过状态4呼吸速率的显著降低实现的。在雌性大鼠中,损伤后用黄体酮治疗并未显著改善线粒体RCR。正常(未受伤)雄性大鼠的线粒体谷胱甘肽含量低于正常雌性大鼠。TBI后,黄体酮仅能防止雄性大鼠线粒体谷胱甘肽的丢失。在CCI后7天,黄体酮治疗的雌性大鼠组织损失减少。未来的研究将针对与神经功能结果测试的相关性。这些临床前研究可为规划未来儿童TBI黄体酮治疗的临床试验提供信息。